Jazz Pharmaceuticals plc vs ADMA Biologics, Inc.: Annual Revenue Growth Compared

Biotech Giants: A Decade of Revenue Growth Compared

__timestampADMA Biologics, Inc.Jazz Pharmaceuticals plc
Wednesday, January 1, 201459155451172875000
Thursday, January 1, 201571776331324803000
Friday, January 1, 2016106610371487973000
Sunday, January 1, 2017227605601618693000
Monday, January 1, 2018169852901890922000
Tuesday, January 1, 2019293490832161761000
Wednesday, January 1, 2020422197832363567000
Friday, January 1, 2021809426253094238000
Saturday, January 1, 20221540796923659374000
Sunday, January 1, 20232582149993834204000
Loading chart...

Unleashing the power of data

A Tale of Two Biotechs: Revenue Growth from 2014 to 2023

In the dynamic world of biotechnology, revenue growth is a key indicator of a company's success and market position. Over the past decade, Jazz Pharmaceuticals plc and ADMA Biologics, Inc. have showcased contrasting trajectories in their annual revenue growth.

Jazz Pharmaceuticals, a leader in the pharmaceutical industry, has seen its revenue grow by over 227% from 2014 to 2023, reaching nearly $3.8 billion. This impressive growth underscores its strategic acquisitions and robust product pipeline. Meanwhile, ADMA Biologics, a smaller player, has experienced a staggering 4,260% increase in revenue, albeit from a much smaller base, highlighting its rapid expansion and increasing market presence.

This comparison not only reflects the diverse strategies of these companies but also the broader trends in the biotech sector, where innovation and strategic growth are paramount.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025